Refer to…
Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trialBrandon Kirsch et al. J Am Acad Dermatol. 2020 Jun.
Results: At the end of therapy, 70%, 79%, 76%, and 54% of participants in the 5%, 10%, 15%, and vehicle groups exhibited ≥1-point improvement in HDSM-Ax (P < .05).
Assuming the pulled release is accurate. They may have decided to approve a midpoint (chose 12.45%) between 10-15% considering 10% elicited the slightly better results v 15% (79-76%).
note: Approval in Japan is for 5% sofpironium bromide gel.
So no problem at all.
Ann: Trading Halt, page-290
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.8¢ |
Change
-0.008(2.17%) |
Mkt cap ! $624.4M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.0¢ | 33.5¢ | $865.7K | 2.555M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 245710 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 132061 | 5 |
View Market Depth
| Last trade - 11.55am 04/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |